Effector TherapeuticsEFTR
13F holders, Q2 2024 (June 30)16holders +1
8new positions
7sold out
$0.29avg. 13F price*
At the end of Q2 2024, 16 institutions reported holding Effector Therapeutics Inc. (EFTR) in their 13F filings, up 1 from Q1 2024. 8 opened new positions and 7 sold out. The largest holders were Sabby Management, LLC ($102K), Carlyle Group Inc. ($56K) and UBS Group AG ($18K).
- Company
- Effector Therapeutics Inc.
- CUSIP
- 28202V207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $140K |
| Exits | 7 | $7.1M |
All 13F filers, Q1 2024 → Q2 2024: 494,574 shares bought and 565,424 shares sold, net −70,850 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| Sabby Management, LLC | 1.52% | New | 352,084 | $102K |
| Carlyle Group Inc. | 0.01% | No change | 192,884 | $56K |
| UBS Group AG | 0.00% | New | 61,667 | $18K |
| Geode Capital Management, LLC | 0.00% | Add +13.2% | 25,583 | $7K |
| Vanguard Group Inc. | 0.00% | Reduce -72.9% | 25,070 | $7K |
| HRT Financial LP | 0.00% | New | 21,528 | $6K |
| Jane Street Group, LLC | 0.00% | New | 18,669 | $5K |
| Virtu Financial LLC | 0.00% | New | 18,021 | $5K |
| Two Sigma Investments, LP | 0.00% | New | 11,115 | $3K |
| Sea Otter Advisors LLC | 0.03% | No change | 10,557 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +539.2% | 9,805 | $3K |
| Morgan Stanley | 0.00% | Reduce -85.1% | 240 | $70 |
| Barclays PLC | 0.00% | New | 100 | $29 |
| Bank of America Corp. | 0.00% | New | 31 | $9 |
| Qube Research & Technologies Ltd | 0.00% | No change | 3 | $1 |
| Royal Bank of Canada | 0.00% | Add +26.4% | 546 | $0 |
"% of holder's portfolio" is EFTR's weight in each manager's 13F, not the share of Effector Therapeutics Inc. the manager owns.